Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 36Terminated 6No longer available 4Recruiting 3Active not recruiting 3Withdrawn 2Suspended 1

Sponsor Class

OTHER 21INDUSTRY 3NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 2Thoracic 1Myeloid 1Dermatologic 1

Conditions

Glioma 2Recurrence 1Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Melanoma 1Lung Neoplasms 1Histiocytosis, Langerhans-Cell 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × dabrafenib × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT03340506 2026-04-20

Dabrafenib and/or Trametinib Rollover Study

Novartis

Phase 4 Recruiting
100 enrolled
CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recruiting
110 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡